Business
Press Release Mar 14 2023
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 14, 2023, titled "Glenmark Pharmaceuticals receives ANDA approval for Clindamycin HydrochlorideCapsules USP, 75 mg, 150 mg, and 300 mg".
About this update from Glenmark Pharmaceuticals Limited
[{"type":"text","content":" Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 14, 2023, titled \"Glenmark Pharmaceuticals receives ANDA approval for Clindamycin HydrochlorideCapsules USP, 75 mg, 150 mg, and 300 mg\". View Attachment","length":383,"tagName":"div"}]